LigaChem Biosciences inks dual antibody licensing deals with NovaRock for ADC drug development

CAR-T Digest - August 2020

05 June 2025: LigaChem Biosciences inks dual antibody licensing deals with NovaRock for ADC drug development

LigaChem Biosciences has signed two global licensing agreements with NovaRock Biotherapeutics to acquire exclusive rights to develop ADCs targeting novel antigens overexpressed in solid tumors such as lung, colorectal, gastric, and pancreatic cancers
These targets currently have no approved ADC therapies, positioning LigaChem to address significant unmet medical needs and capitalize on growing global interest in these antigens
The company plans to integrate NovaRock’s antibody technology with its in-house ADC platform, aiming to accelerate development timelines and prepare the candidates for global out-licensing
This deal is part of LigaChem’s broader “VISION 2030” strategy, which focuses on advancing 3–5 new ADC candidates annually and progressing them into clinical trials within two years